Loading
A phase 2 trial of Cemiplimab, Fianlimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients is a phase 2 interventional study registered as NCT03916627 by Regeneron Pharmaceuticals, with 65 participants enrolled, started 2019-07-23 and due to reach its primary completion in 2025-03-31. Interventions recorded: cemiplimab, Platinum Doublet, fianlimab. Conditions listed: Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fianlimab, Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Head and neck squamous cell carcinoma.
Shares Fianlimab, Regeneron, Cemiplimab, Small-cell lung cancer.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Fianlimab, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/